10-Q: Psychemedics Corporation Announces Q2 2024 Results and Plans to Go Private

Psychemedics Corporation reported a decrease in revenue and profit for Q2 2024 and announced a plan to go private through a reverse/forward stock split and delisting from the Nasdaq.

Summary

• Psychemedics Corporation's revenue decreased by 15% for the three months ended June 30, 2024, compared to the same period in 2023, primarily due to lower testing volumes.
• The company's gross profit decreased by 25% to $1.6 million for the three months ended June 30, 2024, compared to $2.1 million in 2023.
• Operating expenses decreased slightly, but the company still reported an operating loss of $899 thousand for the quarter.
• The company's net loss for the quarter was $827 thousand, compared to a net loss of $726 thousand in the same period last year.
• For the six months ended June 30, 2024, revenue decreased by 12% and the net loss was $1.515 million.
• The company plans to go private through a reverse/forward stock split, which will result in some shareholders being cashed out at $2.35 per share.
• The company has entered into a stock purchase agreement to raise up to $3.75 million to fund the transaction and for working capital.
• The company anticipates annual savings exceeding $900,000 by going private.

Sentiment

Score: 3

Explanation: The document indicates a significant downturn in financial performance and a major strategic shift to go private, which is generally viewed negatively by investors. The company is facing challenges and is taking drastic action to address them.

Positives

• The company anticipates annual savings exceeding $900,000 by going private.
• The company has secured a stock purchase agreement to raise up to $3.75 million to fund the going private transaction and for working capital.
• The company believes its allowance for credit losses related to its accounts receivable remained adequate as of June 30, 2024.
• The company received a waiver from the lender for not being in compliance with the fixed charge coverage ratio as of June 30, 2024.

Negatives

• Revenue decreased by 15% for the three months ended June 30, 2024, compared to the same period in 2023.
• Gross profit decreased by 25% for the three months ended June 30, 2024.
• The company reported a net loss of $827 thousand for the quarter.
• The company's operating activities used net cash of $353 thousand for the six months ended June 30, 2024.
• The company was not in compliance with the fixed charge coverage ratio as of June 30, 2024.
• The company's revenues were impacted by lower volumes from customers experiencing the effects of the general economic conditions, continued labor shortage related to hiring and changing customer priorities.

Risks

• The company's future operating results and cash flows could be adversely affected by economic conditions.
• There is no assurance that additional financing will be available on acceptable terms.
• The company may not be able to achieve its business plans.
• The company faces risks associated with changes in U.S. and foreign government regulations.
• The company faces competition from other companies.
• The company may experience risks of information technology system failures and data security breaches.
• The company may not be able to attract, develop and retain executives and other qualified employees.
• The company may not be able to obtain and protect intellectual property rights.
• The company faces litigation risks.
• The company's ability to maintain its reputation and brand image is a risk.
• The company's ability to achieve its business plans is a risk.
• The company faces risks related to the consummation of the going private transaction, including regulatory review and stockholder approval.

Future Outlook

The company plans to go private through a reverse/forward stock split and delist from the Nasdaq, aiming to reduce costs and focus on core operations. The company anticipates annual savings exceeding $900,000 as a result of the transaction.

Management Comments

• Management currently believes that existing funds, together with future operating profits, should be adequate to fund anticipated working capital requirements for at least the next 12 months.
• The Board has determined the Transaction is in the best interests of all of the Company's stockholders.
• The Company is taking these steps to avoid the substantial cost and expense of being a public reporting company and to focus the Company's resources on enhancing long-term stockholder value.

Industry Context

The company's performance reflects challenges in the drug testing industry, including economic pressures and labor shortages. The decision to go private may be a strategic move to reduce costs and focus on core operations in a competitive market.

Comparison to Industry Standards

• It is difficult to compare Psychemedics directly to industry standards due to its unique hair follicle drug testing technology and the lack of publicly available data for similar private companies.
• Publicly traded competitors in the broader drug testing market, such as Quest Diagnostics and LabCorp, typically have much larger revenue bases and more diversified service offerings.
• The decision to go private suggests that Psychemedics may be facing challenges in maintaining profitability and growth as a public company, which is not uncommon for smaller companies in the healthcare sector.
• The company's revenue decline and net loss are concerning when compared to the performance of larger, more established players in the industry.

Stakeholder Impact

• Shareholders owning fewer shares than the reverse stock split ratio denominator will be cashed out at $2.35 per share.
• Continuing shareholders will not receive cash for fractional shares resulting from the reverse stock split.
• The company will no longer be subject to the same level of public reporting requirements, which may reduce transparency for stakeholders.
• Employees may be impacted by the company's restructuring and cost-cutting measures.
• Customers may experience changes in service or pricing as the company adjusts to its new private structure.

Next Steps

• The company will file a preliminary proxy statement with respect to the going private transaction.
• The company will seek stockholder approval for the reverse/forward stock split and the stock purchase agreement at the 2024 Annual Meeting of Stockholders.
• The company will determine the final reverse stock split ratio prior to the closing of the transaction.
• The company will terminate the registration of its common stock with the SEC and delist from the Nasdaq Capital Market after the transaction is completed.

Key Dates

Keywords

reverse stock split, going private, delisting, stock purchase agreement, financial results, Q2 2024, revenue decrease, net loss, Psychemedics Corporation, drug testing